scout
|Videos|June 27, 2017

Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Due to this analysis, it is important for the patients who are candidates for sipuleucel-T to receive it early in their treatment course since that is where the best outcomes were seen, explains Sartor.

This could lead to the hypothesis that perhaps African-American patients are more responsive to immunotherapy across many different cancer types, but this needs to be proven, states Sartor.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME